Edward Nash
Stock Analyst at Canaccord Genuity
(4.92)
# 213
Out of 4,609 analysts
388
Total ratings
54.3%
Success rate
30.1%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintained: Buy | $62 → $70 | $62.76 | +11.54% | 40 | Aug 6, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $129 | $105.48 | +22.30% | 5 | Aug 6, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Buy | $153 | $73.09 | +109.33% | 2 | Aug 5, 2026 | |
| CORT Corcept Therapeutics | Reiterated: Buy | $135 → $161 | $110.69 | +45.45% | 55 | Jul 30, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $107 → $114 | $33.51 | +240.20% | 9 | Jul 30, 2026 | |
| RANI Rani Therapeutics Holdings | Reiterated: Buy | $5 | $0.78 | +541.03% | 19 | Jul 30, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Buy | $578 → $587 | $514.12 | +14.18% | 41 | Jul 29, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Reiterated: Buy | $64 → $98 | $78.08 | +25.51% | 4 | Jul 29, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Buy | $62 → $60 | $41.06 | +46.13% | 12 | Jul 22, 2026 | |
| CNTB Connect Biopharma Holdings | Maintained: Buy | $6 | $2.18 | +175.23% | 3 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $130 → $135 | $134.23 | +0.66% | 15 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11.21 | $1.90 | +489.75% | 24 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 | $2.33 | +972.96% | 3 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 | $1.05 | +185.71% | 15 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $49 | $8.64 | +467.13% | 11 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $101 | $50.53 | +99.88% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $4.72 | +323.73% | 14 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $4.68 | n/a | 8 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2 | $4.32 | n/a | 6 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $15 | $0.58 | n/a | 15 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $1 | $0.000001 | n/a | 2 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $6.65 | n/a | 2 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 | $1.77 | n/a | 1 | Jun 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 → $39 | $5.93 | n/a | 9 | May 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $176 | $15.93 | n/a | 15 | Feb 27, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $48 → $64 | $44.24 | n/a | 2 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $126 → $117 | $59.91 | n/a | 14 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 → $71 | $24.93 | n/a | 11 | Jan 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $156 | $54.99 | n/a | 1 | Sep 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $132 | $867.94 | n/a | 1 | Sep 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 → $4 | $13.53 | n/a | 3 | Jun 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $17.88 | n/a | 1 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $23 | $6.80 | n/a | 2 | May 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $0.0001 | n/a | 1 | Sep 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $2 | $0.000001 | n/a | 2 | May 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $6 | $4.10 | n/a | 8 | May 5, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | $14.01 | n/a | 3 | Mar 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 → $11 | $4.15 | n/a | 3 | Sep 4, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $0.0994 | n/a | 1 | Jun 17, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $12.63 | n/a | 2 | May 3, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $28.80 | n/a | 1 | Jan 28, 2013 |
Travere Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $62 → $70
Current: $62.76
Upside: +11.54%
Kymera Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $129
Current: $105.48
Upside: +22.30%
Nektar Therapeutics
Aug 5, 2026
Maintained: Buy
Price Target: $153
Current: $73.09
Upside: +109.33%
Corcept Therapeutics
Jul 30, 2026
Reiterated: Buy
Price Target: $135 → $161
Current: $110.69
Upside: +45.45%
Viking Therapeutics
Jul 30, 2026
Reiterated: Buy
Price Target: $107 → $114
Current: $33.51
Upside: +240.20%
Rani Therapeutics Holdings
Jul 30, 2026
Reiterated: Buy
Price Target: $5
Current: $0.78
Upside: +541.03%
Madrigal Pharmaceuticals
Jul 29, 2026
Reiterated: Buy
Price Target: $578 → $587
Current: $514.12
Upside: +14.18%
Kiniksa Pharmaceuticals International,
Jul 29, 2026
Reiterated: Buy
Price Target: $64 → $98
Current: $78.08
Upside: +25.51%
Celldex Therapeutics
Jul 22, 2026
Reiterated: Buy
Price Target: $62 → $60
Current: $41.06
Upside: +46.13%
Connect Biopharma Holdings
Jun 30, 2026
Maintained: Buy
Price Target: $6
Current: $2.18
Upside: +175.23%
Jun 23, 2026
Downgraded: Hold
Price Target: $130 → $135
Current: $134.23
Upside: +0.66%
May 19, 2026
Reiterated: Buy
Price Target: $11.21
Current: $1.90
Upside: +489.75%
May 14, 2026
Rated: Buy
Price Target: $25
Current: $2.33
Upside: +972.96%
May 12, 2026
Maintained: Hold
Price Target: $3
Current: $1.05
Upside: +185.71%
May 12, 2026
Maintained: Buy
Price Target: $49
Current: $8.64
Upside: +467.13%
May 8, 2026
Reiterated: Buy
Price Target: $101
Current: $50.53
Upside: +99.88%
Apr 2, 2026
Maintained: Buy
Price Target: $20
Current: $4.72
Upside: +323.73%
Oct 2, 2024
Maintained: Buy
Price Target: $9
Current: $4.68
Upside: n/a
May 17, 2023
Maintained: Hold
Price Target: $2
Current: $4.32
Upside: n/a
Aug 8, 2022
Downgraded: Hold
Price Target: $5 → $15
Current: $0.58
Upside: n/a
Jul 29, 2022
Downgraded: Hold
Price Target: $12 → $1
Current: $0.000001
Upside: n/a
May 18, 2021
Maintained: Buy
Price Target: $25
Current: $6.65
Upside: n/a
Jun 5, 2019
Downgraded: Hold
Price Target: $5
Current: $1.77
Upside: n/a
May 20, 2019
Maintained: Buy
Price Target: $60 → $39
Current: $5.93
Upside: n/a
Feb 27, 2019
Reiterated: Buy
Price Target: $176
Current: $15.93
Upside: n/a
Feb 26, 2019
Maintained: Buy
Price Target: $48 → $64
Current: $44.24
Upside: n/a
Feb 25, 2019
Maintained: Buy
Price Target: $126 → $117
Current: $59.91
Upside: n/a
Jan 23, 2019
Maintained: Buy
Price Target: $54 → $71
Current: $24.93
Upside: n/a
Sep 24, 2018
Maintained: Buy
Price Target: $156
Current: $54.99
Upside: n/a
Sep 17, 2018
Maintained: Buy
Price Target: $132
Current: $867.94
Upside: n/a
Jun 27, 2018
Downgraded: Hold
Price Target: $22 → $4
Current: $13.53
Upside: n/a
Jun 25, 2018
Initiated Coverage: Buy
Price Target: $26
Current: $17.88
Upside: n/a
May 16, 2018
Maintained: Buy
Price Target: $26 → $23
Current: $6.80
Upside: n/a
Sep 18, 2017
Maintained: Buy
Price Target: $24
Current: $0.0001
Upside: n/a
May 16, 2017
Reiterated: Hold
Price Target: $1 → $2
Current: $0.000001
Upside: n/a
May 5, 2017
Reiterated: Hold
Price Target: $3 → $6
Current: $4.10
Upside: n/a
Mar 7, 2017
Reiterated: Hold
Price Target: $9
Current: $14.01
Upside: n/a
Sep 4, 2014
Downgraded: Hold
Price Target: $14 → $11
Current: $4.15
Upside: n/a
Jun 17, 2013
Initiated Coverage: Buy
Price Target: n/a
Current: $0.0994
Upside: n/a
May 3, 2013
Downgraded: Sell
Price Target: n/a
Current: $12.63
Upside: n/a
Jan 28, 2013
Initiated Coverage: Buy
Price Target: n/a
Current: $28.80
Upside: n/a